Cabinet nod to Rs 3000 crore for 3 Bulk Drug parks , Rs 6950 crore Production Linked Incentive Scheme for domestic production of APIs
Delhi: The Indian pharmaceutical industry is the 3rd largest in the world by volume. However, despite this achievement, India is significantly dependent on the import of basic raw materials, viz., Bulk Drugs that are used to produce medicines. In some specific bulk drugs, the import dependence is 80 to 100%.
A continuous supply of drugs is necessary to ensure the delivery of affordable healthcare to citizens. Any disruption in supplies can have a significant adverse impact on Drug Security, which is also linked to the overall economy of the country. Self-sufficiency in the manufacturing of bulk drugs is highly required.
In order to promote domestic production of APIs and ensure that there is no shortage especially in the light of the coronavirus spread in the country, the Union Cabinet has approved the promotion of domestic manufacturing of critical Key Starting Materials/Drug Intermediates and Active Pharmaceutical Ingredients in the country
The Union Cabinet chaired by the Prime Minister, Shri Narendra Modi has approved the following schemes:
- The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for the next five years.
- for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs 6,940 crore for the next eight years.
Details of the projects would include
- Promotion of Bulk Drug Parks
- The decision is to develop 3 mega Bulk Drug parks in India in partnership with States.
- The government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park.
- Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant, etc.
- A sum of Rs. 3,000 crore has been approved for this scheme for the next 5 years.
- Production Linked Incentive Scheme
- Financial incentives will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years.
- Out of 53 identified bulk drugs, 26 are fermentation-based bulk drugs and 27 are chemical synthesis based bulk drugs.
- The rate of incentive will be 20 % (of incremental sales value) for fermentation-based bulk drugs and 10% for chemical synthesis based bulk drugs.
- A sum of Rs. 6,940 crore has been approved for the next 8 years.
- Promotion of Bulk Drug Parks:
- The scheme is expected to reduce the manufacturing cost of bulk drugs in the country and dependency on other countries for bulk drugs.
- Production Linked Incentive Scheme:
- The scheme intends to boost domestic manufacturing of critical KSMs/Drug Intermediates and APIs by attracting large investments in the sector to ensure their sustainable domestic supply and thereby reduce India's import dependence on other countries for critical KSMs/Drug Intermediates and APIs.
- It will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over 8 years.
In terms of implementation, for the Promotion of Bulk Drug Parks, the scheme will be implemented by State Implementing Agencies (SIA) to be set up by the respective State Governments and the target is to set up 3 mega Bulk Drug Parks.
Similarly for the Production Linked Incentive Scheme, the scheme will be implemented through a Project Management Agency (PMA) to be nominated by the Department of Pharmaceuticals. The Scheme will be applicable only for the manufacturing of 53 identified critical bulk drugs (KSMs/Drug Intermediates and APIs).
With the move being approved, Common infrastructure facilities would be created with the financial assistance under the sub-scheme in 03 Bulk Drug Parks.It is expected to reduce manufacturing costs and dependency on other countries of Bulk Drugs in the country.
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at firstname.lastname@example.org. Check out more about our bureau/team here